Randomized, single blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis

Journal of Cystic Fibrosis

Volumn 14, Issue 2, 2015, Pages 203-210

  Calabrese, C ^a   Tosco, A ^b   Abete, P ^b   Carnovale, V ^b   Basile, C ^b   Magliocca, A ^b   Quattrucci, S ^c   De Sanctis, S ^c   Alatri, F ^c   Mazzarella, G ^a   De Pietro, L ^a   Turino, C ^a   Melillo, E ^d   Buonpensiero, P ^b   Di Pasqua, A ^b   Raia, V ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d SANTOBONO PAUSILIPON CHILDREN S HOSPITAL   (Italy)

Author keywords

Cystic fibrosis; Glutathione; Therapy

Indexed keywords

GLUTATHIONE; PLACEBO; ANTIOXIDANT;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; CHILD; CONSTIPATION; CONTROLLED STUDY; CYSTIC FIBROSIS; DEHYDRATION; DISTAL INTESTINAL OBSTRUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEMOPTYSIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INTESTINE OBSTRUCTION; INVESTIGATIVE PROCEDURES; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PANCREATITIS; PITYRIASIS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SINGLE BLIND PROCEDURE; THORAX PAIN; TREATMENT DURATION; WALKING; DRUG EFFECTS; DRUG MONITORING; EXERCISE TEST; INHALATIONAL DRUG ADMINISTRATION; LUNG; METABOLISM; OXIDATIVE STRESS; PROCEDURES; SEVERITY OF ILLNESS INDEX; TRANSPORT AT THE CELLULAR LEVEL; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTIOXIDANTS; BIOLOGICAL TRANSPORT; CHILD; CYSTIC FIBROSIS; DRUG MONITORING; EXERCISE TEST; FEMALE; FORCED EXPIRATORY VOLUME; GLUTATHIONE; HUMANS; LUNG; MALE; OXIDATIVE STRESS; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84924295957     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2014.09.014     Document Type: Article

References (29)

1. Kelly F.J. Glutathione: in defence of the lung. Food Chem Toxicol 1999, 37(9-10):963-966.
2. Morris D., Khurasany M., Nguyen T., Kim J., Guilford F., Mehta R., et al. Glutathione and infection. Biochim Biophys Acta 2013, 1830(5):3329-3349.
3. Roum J.H., Buhl R., McElvaney N.G., Borok Z., Crystal R.G. Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol 1993, 75(6):2419-2424.
4. Linsdell P., Hanrahan J.W. Glutathione permeability of CFTR. Am J Physiol 1998, 275(1):C323-C326.
5. Velsor L.W., Kariya C., Kachadourian R., Day B.J. Mitochondrial oxidative stress in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am J Respir Cell Mol Biol 2006, 35(5):579-586.
6. McGrath L.T., Mallon P., Dowey L., Silke B., McClean E., McDonnell M., et al. Oxidative stress during acute respiratory exacerbations in cystic fibrosis. Thorax 1999, 54(6):518-523.
7. Franco R., Panayiotidis M.I., Cidlowski J.A. Glutathione depletion is necessary for apoptosis in lymphoid cells independent of reactive oxygen species formation. J Biol Chem 2007, 282(42):30452-30465.
8. Hudson V.M. New insights into the pathogenesis of cystic fibrosis: pivotal role of glutathione system dysfunction and implications for therapy. Treat Respir Med 2004, 3(6):353-363.
9. Hudson V.M. Rethinking cystic fibrosis pathology: the critical role of abnormal reduced glutathione transport caused by CFTR mutation. Free Radic Biol Med 2001, 30(12):1440-1461.
10. Roum J.H., Borok Z., McElvaney N.G., Grimes G.J., Bokser A.D., Buhl R., et al. Glutathione aerosol suppresses lung epithelial surface inflammatory cell-derived oxidants in cystic fibrosis. J Appl Physiol 1999, 87(1):438-443.
11. Griese M., Ramakers J., Krasselt A., Starosta V., Van Koningsbruggen S., Fischer R., et al. Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis. Am J Respir Crit Care Med 2004, 169(7):822-828.
12. Bishop C., Hudson V.M., Hilton S.C., Wilde C. A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis. Chest 2005, 127(1):308-317.
13. Visca A., Bishop C.T., Hilton S.C., Hudson V.M. Improvement in clinical markers in CF patients using a reduced glutathione regimen: an uncontrolled, observational study. J Cyst Fibros 2008, 7(5):433-436.
14. Griese M., Kappler M., Eismann C., Ballmann M., Junge S., Rietschel E., et al. Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. Am J Respir Crit Care Med 2013, 188(1):83-89.
15. Standardization of Spirometry Update. American Thoracic Society. Am J Respir Crit Care Med 1995, 152(3):1107-1136.
16. A.T.S. Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166(1):111-117.
17. Mahler D., Wells C. Evaluation of clinical methods for rating dyspnoea. Chest 1988, 93:580-586.
18. Baiardini I., Braido F., Fassio O., Tarantini F., Pasquali M., Tarchino F., et al. A new tool to assess and monitor the burden of chronic cough on quality of life: Chronic Cough Impact Questionnaire. Allergy 2005, 60(4):482-488.
19. Monti F., Lupi F., Gobbi F., Agostini F., Miano A., Gee L., et al. Validation of the Italian version of the Cystic Fibrosis Quality of Life Questionnaire (CFQoL), a disease specific measure for adults and adolescent with Cystic Fibrosis. J Cyst Fibros 2008, 7(2):116-122.
20. Flume P.A., Mogayzel P.J., Robinson K.A., Goss C.H., Rosenblatt R.L., Kuhn R.J., et al. Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009, 180(9):802-808.
21. Fuchs H.J., Borowitz D.S., Christiansen D.H., Morris E.M., Nash M.L., Ramsey B.W., et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis: the Pulmozyme Study Group. N Engl J Med 1994, 331:637-642.
22. Horváth I., Hunt J., Barnes P.J., Alving K., Antczak A., Baraldi E., et al. ATS/ERS Task Force on Exhaled Breath Condensate. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 2005, 26(3):523-548.
23. Cesarone M.R., Belcaro G., Carratelli M., Cornelli U., De Sanctis M.T., Incandela L., et al. A simple test to monitor oxidative stress. Int Angiol 1999, 18(2):127-130.
24. Kerem E., Reisman J., Corey M., Canny G.J., Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992, 326:1187-1191.
25. Liou T.G., Adler F.R., Fitzsimmons S.C., Cahill B.C., Hibbs J.R., Marshall B.C. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001, 153:345-352.
26. Cystic Fibrosis Foundation Cystic Fibrosis Foundation Patient Registry 2006 Annual Data Report 2007, Cystic Fibrosis Foundation, Bethesda, Maryland.
27. Liou T.G., Elkin E.P., Pasta D.J., Jacobs J.R., Konstan M.W., Morgan W.J., et al. Year-to-year changes in lung function in individuals with cystic fibrosis. J Cyst Fibros 2010, 9:250-256.
28. Stollar F., Rodrigues J.C., Cunha M.T., Leone C., Adde F.V. Six minute walk test Z score: correlations with cystic fibrosis severity markers. J Cyst Fibros 2012, 11(3):253-256.
29. Kent L., Reix P., Innes J.A., Zielen S., Le Bourgeois M., Braggion C., et al. Lung clearance index: evidence for use in clinical trials in cystic fibrosis. J Cyst Fibros 2014, 13(2):123-138.